BIOCORP
27.9.2021 06:47:07 CEST | Business Wire | Press release
Regulatory News:
BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / Eligible PEA PME), a French company specialized in the design, development, and manufacturing of innovative medical devices, today announces an agreement with Novo Nordisk, a world leader in diabetes care, for the development and distribution (pending successful development) of a Mallya smart add-on device for the Novo Nordisk FlexTouch pen used by people with diabetes.
Mallya is a Bluetooth enabled smart add-on device for pen injectors that collects dose and time of each injection and transfers information in real time to a companion software. Mallya helps people with diabetes maintain a reliable dose log, using technology to help improve understanding and allowing people to dose with confidence.
Most Novo Nordisk's insulins are offered with the FlexTouch pen, and it is part of the launch map for all new insulins. A specific version of Mallya will be developed for FlexTouch, the first prefilled insulin delivery device with no-push-button extension. Due to the unique dosing mechanism of FlexTouch, the push button does not extend at any dose and allows insulin to be administered by pressing the low injection force button. The existing Mallya device had to be redesigned to meet the needs of this mechanism, keeping its accuracy and reliability for the patient.
Directly attached on the disposable pre-filled FlexTouch pen, Mallya will allow seamless and efficient dose logging on FlexTouch, which could help people with diabetes and their HCPs to have more personalized conversations about the disease and treatment compliance.
Biocorp will receive an upfront payment and different milestones are defined staging the development phase. Upon successful development, Novo Nordisk plans to distribute the smart device in selected countries, and Biocorp expects to ramp up production volumes from 2022. Financials and terms of contract are not disclosed.
“Novo Nordisk collaborates with Biocorp as we believe people with diabetes deserve the freedom to decide which solution works best for them. Our Swedish study1 demonstrates the health benefits associated with the use of smart insulin pens. And as we continue launching such smart pens, we also partner with Biocorp to allow even more people with diabetes to reap the benefits connected devices can provide. This collaboration demonstrates our commitment to making diabetes management easier by giving people access to data on medication usage behaviour which is known to potentially result in improved patient outcomes”, said Søren Smed Østergaard, vice president of Digital Health at Novo Nordisk.
“Biocorp is very proud to sign this partnership with the world's leading diabetes company, Novo Nordisk, and it is a huge recognition for our Mallya. Providing almost 50% of the insulin used worldwide, Novo Nordisk distributed more than 500 million insulin pens in 2020, treating close to 30 million patients. The FlexTouch pen is not concerned by Mallya's current version, while used by tens of millions of patients with diabetes in the world, so we are pleased to be working to open up the possibilities of connectivity for the many patients around the world who use this pen. ”, said Éric Dessertenne, CEO of BIOCORP.
ABOUT BIOCORP
Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This smart sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of patients with diabetes. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 70 employees. BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com .
1 “Increased Time in Range and Fewer Missed Bolus Injections After Introduction of a Smart Connected Insulin Pen ”, Diabetes Technology & Therapeutics, Vol: 22(7), 2020.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210926005031/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OKX Launches X-Perps on the Magnificent 7 Stocks, Gold, Silver and Oil for European Traders9.6.2026 13:06:00 CEST | Press release
First MiFID-licensed platform to offer European retail traders 24/7 futures exposure to US stocks, commodities and the world's biggest* indices alongside crypto, on one accountSpaceX X-Perps to be available following IPO on June 12 OKX, a leading global fintech company and crypto trading platform, today launched 13 new X-Perp markets for traders across Europe, giving retail users direct access to futures on the "Magnificent 7" tech stocks, four major commodities and the world's biggest* indices. From today, OKX customers in Europe can trade futures on Apple, Amazon, Alphabet, Meta, Microsoft, Nvidia and Tesla, alongside Gold, Silver, WTI Crude Oil and Brent Crude Oil. SPY and QQQ X-Perps are also available, allowing Europeans to build wealth by offering price exposure to the 500 largest US companies and the 100 largest non-financial Nasdaq companies respectively. On Friday June 12, following its IPO, X-Perps on SpaceX will also become available. All markets are available 24/7, with up
Promega Receives SBTi Validation for Near-Term Science-Based Emissions Reduction Targets9.6.2026 13:01:00 CEST | Press release
Validated targets cover Scope 1, 2 and 3 emissions, including a supplier engagement commitment reaching 67% of suppliers by spend by 2030 Promega Corporation has received approval from the Science Based Targets initiative for its near-term emissions reduction targets, developed to reflect the current status of climate science. SBTi is a corporate climate organization that develops standards, tools and guidance for setting greenhouse gas emissions reductions targets in line with what is needed to avoid the worst impacts of climate change. “These goals aren’t just a commitment, they represent a verified plan with third-party accountability built in,” says Corey Meek, Corporate Responsibility Program Manager at Promega. “Our SBTi-validated targets reflect a comprehensive understanding of our greenhouse gas emissions across our entire value chain and set a clear, science-aligned standard for what we aim to achieve by 2030.” The Science Based Targets initiative has approved the following ne
IFF’s 2025 Do More Good Report Highlights Progress in Nature-Based Innovation9.6.2026 13:00:00 CEST | Press release
Driving growth for high-performance, sustainable solutions, while enabling customers to avoid 27.2 million metric tons of CO₂e emissions IFF (NYSE: IFF) — a global leader in flavors, fragrances, food ingredients and health & biosciences — released its 2025 Do More Good Report, highlighting the company’s commitment to creating better products and experiences for people and the planet. IFF’s increasingly nature-based portfolio underscores the central role of sustainability and positions its innovation at the intersection of biology and chemistry. Through continued investment in R&D, expanded global innovation partnerships and measurable impact across the value chain, the report demonstrates how IFF is reducing environmental impact while delivering differentiated performance and long-term value for customers and consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608586967/en/ Cover image for IFF’s 2025 Do More Good re
Icon Solutions Showcases How Banks Can Accelerate Digital Asset Innovation with IPF9.6.2026 11:30:00 CEST | Press release
Banks can now deploy digital asset payments faster, without risking fragmentation Icon Solutions – the UK fintech enabling banks to design and implement state-of-the-art payment systems – has released a reference implementation showing how banks can use the Icon Payments Framework (IPF) to accelerate support for payments processing using distributed ledger technology (DLT)-based digital assets. As IPF is agnostic to both the type of digital asset and the DLT network on which they are issued, the risk of fragmentation is reduced as adoption scales. There is growing momentum for digital assets such as stablecoins, tokenised deposits, deposit tokens and central bank digital currencies (CBDCs) to enable faster, cheaper and smarter payments. Yet the emergence of different digital asset types and DLT networks – which must also work with existing financial infrastructure – creates fragmentation and operational complexity for banks. This is compounded by legacy vendor solutions that limit choi
monday.com Appoints Ben Barnett General Manager of EMEA to Drive Next Phase of Regional Growth9.6.2026 10:00:00 CEST | Press release
In 2025, monday.com saw 26% YoY revenue growth in EMEABarnett will be a driving force in monday.com’s biggest transformation yet monday.com (Nasdaq: MNDY), the AI work platform that turns strategy into execution at scale, today announced Ben Barnett’s appointment to General Manager (GM) of Europe, the Middle East and Africa, marking a major milestone in the company’s global expansion. Ben, who has been with monday.com for five years, brings a decade of experience in senior B2B sales roles at software companies and has overseen significant, sustained growth at monday.com in the UK and Ireland since joining in 2021. In his new position, Ben’s priorities include delivering the monday.com’s EMEA go-to-market strategy, fostering key partnerships, and bolstering its newly announced AI work platform. He is based in London. Ben’s promotion comes as monday.com builds on a period of rapid regional success, with EMEA revenue up 26% year-on-year in 2025. Last year, monday.com expanded its regional
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom